



ASX Announcement

25 November 2021

Relocation of head office

SYDNEY Australia Thursday, 25 November 2021 – Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) advises of the relocation of its head office. The relocation from the current office will be effective on Wednesday, 1 December 2021.

From 1 December 2021, the Company's registered office address and principal place of business will be:

Level 1, 3-5 George Street
Leichhardt NSW 2040
Ph +61 (0)2 9099 4750 (unchanged)

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com.